October 22, 2015

JDS Therapeutics, Nutrition21 Complete 1$6 Million Series Round B Of Institutional Equity Financing

JDS Therapeutics, LLC (“JDS”), a privately-held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a $16 million Series B institutional equity financing round led by 1315Capital, a Philadelphia-based investment firm specializing in healthcare..

DOWNLOAD the PDF
DOWNLOAD the PDF

more news

MORE NEWS
Ingredients

Chromax®Lustriva®Nitrosigine®NooLVL®Velositol®Zinmax®

More

AboutMeet the Sales TeamInnovationQualityProduct ProtectionWhere to FindPress RoomBlogContact

Get in Touch

[email protected]

250 Pehle AvenueSuite 200Saddle Brook, NJ 07663

Nutrition21 Proudly Supports the Following Industry Associations

N21 New Footer Image V2 uai Nutrition21

©2023 Nutrition21, LLC. All rights reserved.       

Nitrosigine®, Velositol®, nooLVL®, Lustriva®, Chromax®, Zinmax®, and their associated logos are registered trademarks of Nutrition21, LLC.  All third party trademarks are the property of their respective owners. Nutrition21, LLC's products are protected by a number of patents including, but not limited to: US Patent Nos. 6,809,115; 6,803,456; 7,576,132; 8,062,677; 8,933,022; 9,028,879; 9,119,835; 9,597,404; 9,675,702; 10,183,049; and 10,245,325.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.